Powered By Bing

Stewart Lab: Publications

Browse all Stewart lab publications on PubMed »


  • Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami, Shelat A, Dyer MA. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Lett 442:262-270; 2019.


  • Nimmervoll B, Boulos N, Bianski B, Dapper J, DeCuypere M, Shelat A, Terranova S, Gilbertson H, Gajjar A, Patel Y, Freeman BB 3rd, Onar-Thomas A, Stewart CF, Rousell MF, Guy RK, Merchant TE, Calabrese C, Wright K, Gilbertson RJ. A preclinical multidisciplinary brain tumor board. Clinical Cancer Research. 24: 1654-1666, 2018.

  • Zhong B, Maharaj A, Davis A, Roussel MF, Stewart CF. Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study. J Pharmaceutical Biomedical Analysis. 156: 97-103, 2018.

  • Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF. Phase I trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer. March 2018. doi: 10.1002/pbc.27035.

  • Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicenter phase 2 trial. Lancet Oncology 19:768-784; 2018.

  • Mitchell AB, Vasilyeva A, Gajjar A, Santana VM, Stewart CF. Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients. Pediatr Blood Cancer. December 2018. Doi: 10.1002/pbc.27578.


  • Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncol. 19: 1135-1144, 2017.

  • Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW. Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77.

  • Kala A, Patel YT, Davis A, Stewart CF. Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study. J Chromatogr B Analyt Technol Biomed Life Sci 1057:110-117.

  • Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer 123:3602-3608.

  • Leong R, Zhao H, Reaman G, Liu Q, Wang Y, Stewart CF, Burckart G. Bridging Adult Experience to Pediatrics in Oncology Drug Development. J Clin Pharmacol 57 Suppl 10:S129-S135.

  • Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol 32: 1575-1584.

  • Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol 80:1013-1026.

  • Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int J Cancer 141:1469-1477.

  • Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF. Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients with Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314.

  • Stewart CF, Robinson GW. Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies. Clin Pharmacol Ther 102:752-753.


  • Roberts MS, Selvo NS, Roberts JK, Daryani VM, Owens TS, Harstead KE, Gajjar A, Stewart CF. Determination of ethotrexate, 7-ydroxymethotrexate, and 2,4-diamino-N-methylpteroic acid by LC-MS/MS in plasma a cerebrospinal fluid and application in a pharmacokinetic analysis of high-dose methotrexate. J Liq Chromatogr 39:745-751.

  • Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, and Pappo A. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. Pediatr Blood Cancer 7:1207-13.

  • Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R.  A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent or Refractory Central Nervous System Malignancies: a Pediatric Brain Tumor Consortium Study. J Neurooncol 129:443-51.

  • Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A. Phase II Evaluation of Sunitinib in the Treatment of Recurrent or Refractory High-Grade Glioma or Ependymoma in Children: a Children’s Oncology Group Study ANS1021. Cancer Med 5:1416-24.

  • Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajar A, Gilbertson RJ, Wright KD, Stewart CF. Translational pharmacokinetic-pharmacodynamic modeling and simulation: optimizing 5-fluorouracil dosing in children with pediatric ependymoma. CPT Pharmacometrics Syst Pharmacol 5:211-221, 2016.

  • Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, and Stewart CF. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos 44:1116-22, 2016.

  • Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, and Gilbertson RJ.  Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29: 508-22, 2016.

  • Patel YT, Jacus MO, Davis AD, Boulos N, Turner DC, Vuppala PK, Freeman BB, 3rd, Gilbertson RJ, and Stewart CF. Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.  Drug Metab Dispos 44:591-4, 2016.

  • Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA,Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, and Krull KR. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncol 2:201-8, 2016.

  • Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB, 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, and Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.  J Neurooncol 126:225-34, 2016.

  • Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, and Stewart CF. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet 55:297-311, 2016.


  • Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, and Gajjar A. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 17:1620-7, 2015.

  • Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR,      Fayad LM, Madewell JE, Navid F, Daw NC, and Reddick WE. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer 113: 1282-8, 2015.

  • Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst 31:1283-1289, 2015.

  • Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib exerts targeted efficacy against recurrent SHH-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies – PBTC-025B and PBTC-032. J Clin Oncol 33:2646-2654, 2015.

  • Morfouace M, Cheepala SB, Jackson S, Fukuda Y, Patel YT, Soghra F, Kawauchi D, Shelat AA, Stewart CF, Sorrentino B, Schuetz JD, Roussel MF.  ABCG2 transporter expression impacts Group3 medulloblastoma response to chemotherapy.  Cancer Res 75: 3879-3889, 2015.

  • Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemotherap Pharmacol 75:495-503, 2015.

  • Jacus MO, Rahija R, Davis A, Throm SL, Stewart CF. Observational evaluation of mice during cerebral microdialysis procedures used in pediatric brain tumor research. J Am Assoc Lab Anim Sci 54: 304-10, 2015.

  • Xu H, Robinson GW, Huang Jie, Lim JY-S, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JY. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics 47:263-266, 2015.

  • Patel Y, Jacus M, Boulos N, Dapper J, David A, Vuppala P, Freeman III B, Mohankumar K, Throm S, Gilbertson R, Stewart CF. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer Chemotherap Pharmacol 75:897-906, 2015.

  • Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P, Ward D, Gajjar A, Stewart CF. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75:27-35, 2015.

  • Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A. Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75:181-93, 2015.


  • Roberts MS, Turner DC, Broniscer A, Stewart CF. Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Chromatography B 960C:151-157, 2014.

  • Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB III, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 20:1-10, 2014.

  • Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Robinson S, Turner D, Zindy F, Wang Y-D, Finkelstein D, Bihannic L, Puget S, Ayrault O, Li X-N, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25(4):516-529, 2014.

  • Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. Eur J Pharm Sci 57:41-7, 2014.

  • Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.


  • Yang JJ, Lim JY-S, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, Shuyu E, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children with Cancer. Clinical Pharmacol Therap 94:252-9, 2013.

  • Broniscer A, Baker SD, Wetmore C, Pai Panadiker A, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 19: 3050-3058, 2013.

  • Roberts MS, Turner DC, Owens TS, Ramachandran A, Wetmore C, Throm SL, Stewart CF. Determination of crenolanib in human serum and cerebrospinal fluid by liquid-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). J Chrom B 292:1-5, 2013.

  • Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. Pediatr Blood Cancer 60:627-632, 2013.


  • Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, McCarville MB, Merchant TE, Brennan R, Free TM, Given V, Haik BG, Rodriguez-Galindo C, Wilson MW.  Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.  Cancer 15:5663-70, 2012.

  • Steinle JJ, Zhang Q, Thompson KE, Toutounchian J, Yates CR, Soderland C, Wang F, Stewart CF, Haik BG, Williams JS, Jackson JS, Mandrell TD, Johnson D, Wilson MW.  Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.  Invest Ophthalmol Vis Sci 53:2439-45, 2012.

  • Kasow KA, Stewart CF, Barfield RC, Wright NL, Li C, Srivastava DK, Leung W, Horwitz EM, Bowman LC, Handgretinger R, Hale GA.  A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up.  Bone Marrow Transpl 47:1448-54, 2012.

  • Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR.  Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.  Cancer 118:4321-30, 2012.

  • Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM.  A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.  Invest New Drugs 30:1660-70, 2012.

  • McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C.  Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.  Pediatr Blood Cancer 58:372-9, 2012.


  • Bai F, Johnson J, Wang F, Yang L, Broniscer A, Stewart CF. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:2561-6, 2011.

  • Elmeliegy MA, Carcaboso AM, L Chow LM, Zhang ZM, Calabrese C, Throm SL, Wang F, Baker SJ, Stewart CF. Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci 100:4210-4214; 2011.

  • Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384-99, 2011.

  • Zhang F, Throm SL, Murley LL, Miller LA, Zatechka DS, Guy RK, Kennedy R, Stewart CF. MDM2 Antagonist Nutlin-3a Reverses Mitoxantrone Resistance by Inhibiting Breast Cancer Resistance Protein Mediated Drug Transport. Biochem Pharmacol 82:24-24, 2011.

  • Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99, 2011.

  • Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF. Whole-body physiologically-based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Disp 39:15-21, 2011.